Sat, Jan 31, 2015, 11:17 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

frenzychess 1 post  |  Last Activity: Dec 28, 2014 12:06 AM Member since: Sep 3, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Everything. Too bad the changes are so small and take so much time. That has given those FDA monsters a chance to cover their tracks a bit. The latest script numbers are heartening, since there is no reason currently for there even to be a Vascepa, (generics are far less for insurers and the FDA hasn't given them any reason to think Vascepa is any better). The tiny window between approval for very high trigs and the denial of ANCHOR gave some doctors a chance to try the drug. It takes a good 2 years or so before larger differences between all the other triglyceride reducing drugs and Vascepa appear. We're just getting into that stage and apparently some physicians are just now seeing the bigger picture up close. Still, the differences are not big enough at this point to be detectable for most doctors, (it should become outright apparent after about 4 years). Amarin might make it, but this injustice for patients around the country is just disgusting. The FDA will continue on this path apparently until later this year or early 2016 when preliminary results from Reduce It show the best drug in the world has been denied wider access due to greed. I hope they all get fired and written up and exposed. This is not the way the system is supposed to work.

AMRN
1.02-0.01(-0.97%)Jan 30 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.